Merck: efficacy endpoint achieved in RSV
(CercleFinance.com) - Merck announced on Tuesday that clesrovimab, its investigational treatment for bronchiolitis in infants, had met its endpoints in a Phase 2b/3 clinical trial.
This monoclonal antibody administered against the respiratory syncytial virus (RSV) met its efficacy and safety endpoints, notably reducing virus-related lower respiratory tract infections (LRTIs) after 150 days.
Merck - which says it is encouraged by these results - states that it plans to present detailed data from the study at a forthcoming scientific congress, before filing registration applications with health authorities worldwide.
Copyright (c) 2024 CercleFinance.com. All rights reserved.